EXPIRED: Norlase

Eye care is becoming a global public health problem. The number of people at risk of age-related eye disease is set to double to 2 billion by 2050. Diabetes, a major contributor to blindness, already affects an estimated 500 million.

This is exacerbated by a global shortage of eye specialists (ophthalmologists) and the current limitations of the available equipment (photocoagulators), which has seen little innovation since the 1980s. Photocoagulators are used to carry out a type of laser eye surgery; however, due to their high costs, size and low reliability, are currently routinely used by only 15% of ophthalmologists.

Norlase ApS (“Norlase” or the “Company”) was set up in 2014 to address this: it is developing a suite of next-generation semiconductor-based medical laser devices for treating common eye diseases at low cost and high reliability.

Currently raising funds via Wealth Club.

healthcare Medical engineering